Global Long-Acting Monoclonal Antibodies Market 2021 by Company, Regions, Type and Application, Forecast to 2026

1 Market Overview

• 1.1 Product Overview and Scope of Long-Acting Monoclonal Antibodies
• 1.2 Classification of Long-Acting Monoclonal Antibodies by Type
  • 1.2.1 Overview: Global Long-Acting Monoclonal Antibodies Market Size by Type: 2020 Versus 2021 Versus 2026
  • 1.2.2 Global Long-Acting Monoclonal Antibodies Revenue Market Share by Type in 2020
  • 1.2.3 Murine Source
  • 1.2.4 Chimeric Source
  • 1.2.5 Human Source
• 1.3 Global Long-Acting Monoclonal Antibodies Market by Application
  • 1.3.1 Overview: Global Long-Acting Monoclonal Antibodies Market Size by Application: 2020 Versus 2021 Versus 2026
  • 1.3.2 Cancer
  • 1.3.3 Autoimmune Diseases
  • 1.3.4 Inflammatory Diseases
  • 1.3.5 Infectious Diseases
  • 1.3.6 Others
• 1.4 Global Long-Acting Monoclonal Antibodies Market Size & Forecast
• 1.5 Global Long-Acting Monoclonal Antibodies Market Size and Forecast by Region
  • 1.5.1 Global Long-Acting Monoclonal Antibodies Market Size by Region: 2016 VS 2021 VS 2026
  • 1.5.2 Global Long-Acting Monoclonal Antibodies Market Size by Region, (2016-2021)
  • 1.5.3 North America Long-Acting Monoclonal Antibodies Market Size and Prospect (2016-2026)
  • 1.5.4 Europe Long-Acting Monoclonal Antibodies Market Size and Prospect (2016-2026)
  • 1.5.5 Asia-Pacific Long-Acting Monoclonal Antibodies Market Size and Prospect (2016-2026)
  • 1.5.6 South America Long-Acting Monoclonal Antibodies Market Size and Prospect (2016-2026)
  • 1.5.7 Middle East and Africa Long-Acting Monoclonal Antibodies Market Size and Prospect (2016-2026)
• 1.6 Market Drivers, Restraints and Trends
  • 1.6.1 Long-Acting Monoclonal Antibodies Market Drivers
  • 1.6.2 Long-Acting Monoclonal Antibodies Market Restraints
  • 1.6.3 Long-Acting Monoclonal Antibodies Trends Analysis

2 Company Profiles

• 2.1 Eli Lilly
  • 2.1.1 Eli Lilly Details
  • 2.1.2 Eli Lilly Major Business
  • 2.1.3 Eli Lilly Long-Acting Monoclonal Antibodies Product and Solutions
  • 2.1.4 Eli Lilly Long-Acting Monoclonal Antibodies Revenue, Gross Margin and Market Share (2019-2021)
  • 2.1.5 Eli Lilly Recent Developments and Future Plans
• 2.2 Abbott Laboratories
  • 2.2.1 Abbott Laboratories Details
  • 2.2.2 Abbott Laboratories Major Business
  • 2.2.3 Abbott Laboratories Long-Acting Monoclonal Antibodies Product and Solutions
  • 2.2.4 Abbott Laboratories Long-Acting Monoclonal Antibodies Revenue, Gross Margin and Market Share (2019-2021)
  • 2.2.5 Abbott Laboratories Recent Developments and Future Plans
• 2.3 AstraZeneca
  • 2.3.1 AstraZeneca Details
  • 2.3.2 AstraZeneca Major Business
  • 2.3.3 AstraZeneca Long-Acting Monoclonal Antibodies Product and Solutions
  • 2.3.4 AstraZeneca Long-Acting Monoclonal Antibodies Revenue, Gross Margin and Market Share (2019-2021)
  • 2.3.5 AstraZeneca Recent Developments and Future Plans
• 2.4 Amgen
  • 2.4.1 Amgen Details
  • 2.4.2 Amgen Major Business
  • 2.4.3 Amgen Long-Acting Monoclonal Antibodies Product and Solutions
  • 2.4.4 Amgen Long-Acting Monoclonal Antibodies Revenue, Gross Margin and Market Share (2019-2021)
  • 2.4.5 Amgen Recent Developments and Future Plans
• 2.5 Bayer AG
  • 2.5.1 Bayer AG Details
  • 2.5.2 Bayer AG Major Business
  • 2.5.3 Bayer AG Long-Acting Monoclonal Antibodies Product and Solutions
  • 2.5.4 Bayer AG Long-Acting Monoclonal Antibodies Revenue, Gross Margin and Market Share (2019-2021)
  • 2.5.5 Bayer AG Recent Developments and Future Plans
• 2.6 Johnson & Johnson
  • 2.6.1 Johnson & Johnson Details
  • 2.6.2 Johnson & Johnson Major Business
  • 2.6.3 Johnson & Johnson Long-Acting Monoclonal Antibodies Product and Solutions
  • 2.6.4 Johnson & Johnson Long-Acting Monoclonal Antibodies Revenue, Gross Margin and Market Share (2019-2021)
  • 2.6.5 Johnson & Johnson Recent Developments and Future Plans
• 2.7 Pfizer
  • 2.7.1 Pfizer Details
  • 2.7.2 Pfizer Major Business
  • 2.7.3 Pfizer Long-Acting Monoclonal Antibodies Product and Solutions
  • 2.7.4 Pfizer Long-Acting Monoclonal Antibodies Revenue, Gross Margin and Market Share (2019-2021)
  • 2.7.5 Pfizer Recent Developments and Future Plans
• 2.8 GlaxoSmithKline
  • 2.8.1 GlaxoSmithKline Details
  • 2.8.2 GlaxoSmithKline Major Business
  • 2.8.3 GlaxoSmithKline Long-Acting Monoclonal Antibodies Product and Solutions
  • 2.8.4 GlaxoSmithKline Long-Acting Monoclonal Antibodies Revenue, Gross Margin and Market Share (2019-2021)
  • 2.8.5 GlaxoSmithKline Recent Developments and Future Plans
• 2.9 Merck
  • 2.9.1 Merck Details
  • 2.9.2 Merck Major Business
  • 2.9.3 Merck Long-Acting Monoclonal Antibodies Product and Solutions
  • 2.9.4 Merck Long-Acting Monoclonal Antibodies Revenue, Gross Margin and Market Share (2019-2021)
  • 2.9.5 Merck Recent Developments and Future Plans
• 2.10 Novartis
  • 2.10.1 Novartis Details
  • 2.10.2 Novartis Major Business
  • 2.10.3 Novartis Long-Acting Monoclonal Antibodies Product and Solutions
  • 2.10.4 Novartis Long-Acting Monoclonal Antibodies Revenue, Gross Margin and Market Share (2019-2021)
  • 2.10.5 Novartis Recent Developments and Future Plans

3 Market Competition, by Players

• 3.1 Global Long-Acting Monoclonal Antibodies Revenue and Share by Players (2019-2021)
• 3.2 Market Concentration Rate
  • 3.2.1 Top 3 Long-Acting Monoclonal Antibodies Players Market Share
  • 3.2.2 Top 10 Long-Acting Monoclonal Antibodies Players Market Share
  • 3.2.3 Market Competition Trend
• 3.3 Long-Acting Monoclonal Antibodies Players Head Office, Products and Services Provided
• 3.4 Mergers & Acquisitions
• 3.5 New Entrants and Expansion Plans

4 Market Size Segment by Type

• 4.1 Global Long-Acting Monoclonal Antibodies Revenue and Market Share by Type (2016-2021)
• 4.2 Global Long-Acting Monoclonal Antibodies Market Forecast by Type (2021-2026)

5 Market Size Segment by Application

• 5.1 Global Long-Acting Monoclonal Antibodies Revenue Market Share by Application (2016-2021)
• 5.2 Long-Acting Monoclonal Antibodies Market Forecast by Application (2021-2026)

6 North America by Country, by Type, and by Application

• 6.1 North America Long-Acting Monoclonal Antibodies Revenue by Type (2016-2026)
• 6.2 North America Long-Acting Monoclonal Antibodies Revenue by Application (2016-2026)
• 6.3 North America Long-Acting Monoclonal Antibodies Market Size by Country
  • 6.3.1 North America Long-Acting Monoclonal Antibodies Revenue by Country (2016-2026)
  • 6.3.2 United States Long-Acting Monoclonal Antibodies Market Size and Forecast (2016-2026)
  • 6.3.3 Canada Long-Acting Monoclonal Antibodies Market Size and Forecast (2016-2026)
  • 6.3.4 Mexico Long-Acting Monoclonal Antibodies Market Size and Forecast (2016-2026)

7 Europe by Country, by Type, and by Application

• 7.1 Europe Long-Acting Monoclonal Antibodies Revenue by Type (2016-2026)
• 7.2 Europe Long-Acting Monoclonal Antibodies Revenue by Application (2016-2026)
• 7.3 Europe Long-Acting Monoclonal Antibodies Market Size by Country
  • 7.3.1 Europe Long-Acting Monoclonal Antibodies Revenue by Country (2016-2026)
  • 7.3.2 Germany Long-Acting Monoclonal Antibodies Market Size and Forecast (2016-2026)
  • 7.3.3 France Long-Acting Monoclonal Antibodies Market Size and Forecast (2016-2026)
  • 7.3.4 United Kingdom Long-Acting Monoclonal Antibodies Market Size and Forecast (2016-2026)
  • 7.3.5 Russia Long-Acting Monoclonal Antibodies Market Size and Forecast (2016-2026)
  • 7.3.6 Italy Long-Acting Monoclonal Antibodies Market Size and Forecast (2016-2026)

8 Asia-Pacific by Region, by Type, and by Application

• 8.1 Asia-Pacific Long-Acting Monoclonal Antibodies Revenue by Type (2016-2026)
• 8.2 Asia-Pacific Long-Acting Monoclonal Antibodies Revenue by Application (2016-2026)
• 8.3 Asia-Pacific Long-Acting Monoclonal Antibodies Market Size by Region
  • 8.3.1 Asia-Pacific Long-Acting Monoclonal Antibodies Revenue by Region (2016-2026)
  • 8.3.2 China Long-Acting Monoclonal Antibodies Market Size and Forecast (2016-2026)
  • 8.3.3 Japan Long-Acting Monoclonal Antibodies Market Size and Forecast (2016-2026)
  • 8.3.4 South Korea Long-Acting Monoclonal Antibodies Market Size and Forecast (2016-2026)
  • 8.3.5 India Long-Acting Monoclonal Antibodies Market Size and Forecast (2016-2026)
  • 8.3.6 Southeast Asia Long-Acting Monoclonal Antibodies Market Size and Forecast (2016-2026)
  • 8.3.7 Australia Long-Acting Monoclonal Antibodies Market Size and Forecast (2016-2026)

9 South America by Country, by Type, and by Application

• 9.1 South America Long-Acting Monoclonal Antibodies Revenue by Type (2016-2026)
• 9.2 South America Long-Acting Monoclonal Antibodies Revenue by Application (2016-2026)
• 9.3 South America Long-Acting Monoclonal Antibodies Market Size by Country
  • 9.3.1 South America Long-Acting Monoclonal Antibodies Revenue by Country (2016-2026)
  • 9.3.2 Brazil Long-Acting Monoclonal Antibodies Market Size and Forecast (2016-2026)
  • 9.3.3 Argentina Long-Acting Monoclonal Antibodies Market Size and Forecast (2016-2026)

10 Middle East & Africa by Country, by Type, and by Application

• 10.1 Middle East & Africa Long-Acting Monoclonal Antibodies Revenue by Type (2016-2026)
• 10.2 Middle East & Africa Long-Acting Monoclonal Antibodies Revenue by Application (2016-2026)
• 10.3 Middle East & Africa Long-Acting Monoclonal Antibodies Market Size by Country
  • 10.3.1 Middle East & Africa Long-Acting Monoclonal Antibodies Revenue by Country (2016-2026)
  • 10.3.2 Turkey Long-Acting Monoclonal Antibodies Market Size and Forecast (2016-2026)
  • 10.3.3 Saudi Arabia Long-Acting Monoclonal Antibodies Market Size and Forecast (2016-2026)
  • 10.3.4 UAE Long-Acting Monoclonal Antibodies Market Size and Forecast (2016-2026)

11 Research Findings and Conclusion

12 Appendix

• 12.1 Methodology
• 12.2 Research Process and Data Source